Literature DB >> 34059893

Tau mis-splicing correlates with motor impairments and striatal dysfunction in a model of tauopathy.

Ana Damianich1, Carolina Lucia Facal1, Javier Andrés Muñiz1, Camilo Mininni2, Mariano Soiza-Reilly3, Magdalena Ponce De León4, Leandro Urrutia4, German Falasco4, Juan Esteban Ferrario5, María Elena Avale1.   

Abstract

Tauopathies are neurodegenerative diseases caused by the abnormal metabolism of the microtubule associated protein tau (MAPT), which is highly expressed in neurons and critically involved in microtubule dynamics. In the adult human brain, the alternative splicing of exon 10 in MAPT pre-mRNA produces equal amounts of protein isoforms with either three (3R) or four (4R) microtubule binding domains. Imbalance in the 3R:4R tau ratio is associated with primary tauopathies that develop atypical parkinsonism, such as progressive supranuclear palsy and corticobasal degeneration. Yet, the development of effective therapies for those pathologies is an unmet goal. Here we report motor coordination impairments in the htau mouse model of tauopathy which harbour abnormal 3R:4R tau isoforms content, and in contrast to TauKO mice, are unresponsive to l-DOPA. Preclinical-PET imaging, array tomography and electrophysiological analyses indicated the dorsal striatum as the candidate structure mediating such phenotypes. Indeed, local modulation of tau isoforms by RNA trans-splicing in the striata of adult htau mice, prevented motor coordination deficits and restored basal neuronal firing. Together, these results suggest that abnormal striatal tau isoform content might lead to parkinsonian-like phenotypes and demonstrate a proof of concept that modulation of tau mis-splicing is a plausible disease-modifying therapy for some primary tauopathies.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  RNA therapy; microPET; parkinsonism; tau; tauopathies

Mesh:

Substances:

Year:  2021        PMID: 34059893     DOI: 10.1093/brain/awab130

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  3 in total

1.  Does the Anti-Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes.

Authors:  Alberto J Espay; Kariem Ezzat; Andrea Sturchio
Journal:  Mov Disord Clin Pract       Date:  2021-08-31

2.  High altitude is associated with pTau deposition, neuroinflammation, and myelin loss.

Authors:  Diego Iacono; Erin K Murphy; Paul M Sherman; Holly Chapapas; Bianca Cerqueira; Christine Christensen; Daniel P Perl; John Sladky
Journal:  Sci Rep       Date:  2022-04-27       Impact factor: 4.996

Review 3.  Tauopathies: new perspectives and challenges.

Authors:  Yi Zhang; Kai-Min Wu; Liu Yang; Qiang Dong; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2022-04-07       Impact factor: 14.195

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.